Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’…
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (NASDAQ: APLS) stock in the…
…
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter…
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 25.64% and 8.46%, respectively, for the quarter ended December 2024. Do…
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals (APLS) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan)…
SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Apellis Pharmaceuticals ist ein global tätiges biopharmazeutisches Unternehmen, das sich auf die Entwicklung lebensverändernder Therapien spezialisiert hat. Zu den Hauptforschungsbereichen…
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback…
…
…
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.…
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.…
· Statistically significant 68% (p…
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that…
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
Die Apellis Pharmaceuticals Aktie verzeichnete am 12. Oktober 2024 einen leichten Anstieg von 0,08% auf 24,64 EUR. Trotz dieses minimalen…
…
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee…
Apellis Pharmaceuticals shares surge after study results…
· Met the primary endpoint, achieving statistically significant 68% (p…
…
· Rapid reduction in disease activity seen at 12 weeks sustained at one year
· 55% of patients showed…
WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI)…
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
…
Earnings call: Apellis Pharmaceuticals Q1 2024 financials show growth…
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals stock falls following Mizuho comments, price target cut…
WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European…
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals director sells over $1 million in company stock…
Apellis Pharmaceuticals officer sells $564k in company stock…
Apellis Pharmaceuticals VP sells over $10k in company stock…
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
UBS raises Apellis Pharmaceuticals shares target on strong outlook…
…
…
…